ArticleKidney international reports2023
Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis.
Article in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End-Stage Kidney Disease on Hemodialysis.Journal of clinical pharmacology · 2026Article
- Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA.Clinical reviews in allergy & immunology · 2026Review
- Addressing clinical challenges in ANCA-associated vasculitis with real-world evidence.Rheumatology (Oxford, England) · 2026Review
- Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines.Canadian journal of kidney health and disease · 2026Article
- Making use of avacopan in clinical practice.Clinical kidney journal · 2026Review
- Avacopan or Glucocorticoids for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Rapidly Progressive Glomerulonephritis.Kidney international reports · 2025Article
- Avacopan in Double-Positive Vasculitis...Why Not Consider It?: A Case Report.Kidney medicine · 2025Article
- Successful use of avacopan in a case of ANCA-associated vasculitis with treatment-resistant medium-sized vessel involvement.CEN case reports · 2025Article
- Effectiveness and Safety of Avacopan as a Combination Therapy with Glucocorticoids or Monotherapy in Patients with Microscopic Polyangiitis.Internal medicine (Tokyo, Japan) · 2025Article
- Effective management of necrotizing crescentic glomerulonephritis using an aggressive combination therapy including avacopan in a patient double-seropositive for anti-GBM antibodies and ANCA: a case report.CEN case reports · 2025Article
- Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy.Drug design, development and therapy · 2025Review
- Real-World Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.Kidney international reports · 2024Article
- Use of Avacopan in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Estimated Glomerular Filtration Rate <15 ml/min per 1.73 mKidney international reports · 2024Article
- Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.